An overview of PsoProtect’s current data.

Current Data

We are committed to sharing data and are delighted to provide open access to summary data of the cases in PsoProtect. These data are preliminary and include a limited number of cases, so should not be used to inform clinical decision making.

Click here to read our recently published scientific research paper detailing the PsoProtect data, entitled ‘Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study‘.

0
Total number of cases reported

Summary data from PsoProtect’s first 374 cases.

Cases reported by country of assessment:

Country Cases
United Kingdom 135 (36.1%)
Italy 80 (21.4%)
Spain 56 (15.0%)
United States 25 (6.7%)
France 24 (6.4%)
Netherlands 11 (2.9%)
Rest of Europe 22 (5.9%)
Rest of the world 21 (5.6%)

Average age: 50 years
Phenotype of psoriasis: 365 (98%) plaque psoriasis, 8 (2%) pustular psoriasis
Average BMI: 27.4 kg/m2
Average number of days of symptoms from COVID-19: 14 days

Confirmed COVID-19:

Gender:

Smoking history:

Concurrent psoriatic arthritis:

Severity of psoriasis at time of onset of COVID-19 (PGA):

Hospitalization required due to COVID-19:

Systemic medication for psoriasis at time of onset of COVID-19:

Medication Count
Biologic – TNF inhibitor 99
Biologic – IL-23 inhibitor 90
Biologic – IL-17 inhibitor 78
Conventional systemic agent 39
Small molecule inhibitor 26
Biologic and conventional systemic co-therapy 15
Small molecule inhibitor and conventional systemic co-therapy 2
No systemic agent 36

Was the biologic medication for psoriasis stopped during COVID-19 infection:

Outcome of COVID-19: